Finally, two patients presented the PDGRFbeta rearrangement, and thus they received imatinib, effective in MDS cases with PDGFR rearrangement in addition to the chronic myeloid leukemia [29]. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.